更正“瑞非尼后lenvatinib作为三线治疗不可切除肝癌进展的疗效”

IF 3.4 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Hepatology Research Pub Date : 2025-02-04 DOI:10.1111/hepr.14167

{"title":"更正“瑞非尼后lenvatinib作为三线治疗不可切除肝癌进展的疗效”","authors":"","doi":"10.1111/hepr.14167","DOIUrl":null,"url":null,"abstract":"Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, et al. Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatology Research. 2021; 51: 880–9. https://doi.org/10.1111/hepr.13644.In the “Methods” section of the abstract, the text “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with regorafenib followed by sorafenib were enrolled…” was incorrect.This should have read: “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with sorafenib followed by regorafenib were enrolled…”We apologize for this error.","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 5","pages":"781"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.14167","citationCount":"0","resultStr":"{\"title\":\"Correction to “Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression”\",\"authors\":\"\",\"doi\":\"10.1111/hepr.14167\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, et al. Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatology Research. 2021; 51: 880–9. https://doi.org/10.1111/hepr.13644.In the “Methods” section of the abstract, the text “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with regorafenib followed by sorafenib were enrolled…” was incorrect.This should have read: “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with sorafenib followed by regorafenib were enrolled…”We apologize for this error.\",\"PeriodicalId\":12987,\"journal\":{\"name\":\"Hepatology Research\",\"volume\":\"55 5\",\"pages\":\"781\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-02-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.14167\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatology Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/hepr.14167\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hepr.14167","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

平冈A，熊田T，畑中T，田田T， Kariyama K, Tani J，等。瑞非尼后lenvatinib作为三线治疗不可切除肝癌进展的疗效。国际肝病杂志2021；51: 880 - 9。https://doi.org/10.1111/hepr.13644.In摘要的“方法”部分，文本“从2017年6月到2020年10月，63名Child-Pugh A患者接受regorafenib和sorafenib治疗……”是不正确的。这篇文章应该是这样写的：“从2017年6月到2020年10月，63名Child-Pugh A患者接受了索拉非尼和瑞非尼的治疗……”我们为这一错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to “Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression”

Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, et al. Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatology Research. 2021; 51: 880–9. https://doi.org/10.1111/hepr.13644.

In the “Methods” section of the abstract, the text “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with regorafenib followed by sorafenib were enrolled…” was incorrect.

This should have read: “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with sorafenib followed by regorafenib were enrolled…”

We apologize for this error.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hepatology Research 医学-胃肠肝病学

CiteScore

8.30

自引率

14.30%

发文量

124

审稿时长

1 months

期刊介绍： Hepatology Research (formerly International Hepatology Communications) is the official journal of the Japan Society of Hepatology, and publishes original articles, reviews and short comunications dealing with hepatology. Reviews or mini-reviews are especially welcomed from those areas within hepatology undergoing rapid changes. Short communications should contain concise definitive information.